•
Jul 31, 2020

Medtronic Q1 2021 Earnings Report

Medtronic's Q1 2021 financial results reflected a decrease in revenue and EPS due to the impact of the COVID-19 pandemic, but showed signs of recovery with improving procedure volumes and innovative product contributions.

Key Takeaways

Medtronic reported a 13% decrease in Q1 revenue to $6.507 billion, with a GAAP diluted EPS of $0.36 and a non-GAAP diluted EPS of $0.62. The results were impacted by the COVID-19 pandemic, but the company saw a faster than expected recovery with improving procedure volumes.

Q1 revenue decreased by 13% as reported, and approximately 17% organic.

GAAP diluted EPS was $0.36, while non-GAAP diluted EPS was $0.62.

Procedure volumes began to recover around the world.

The company is leveraging its pipeline of innovative products to drive share gains.

Total Revenue
$6.51B
Previous year: $7.49B
-13.2%
EPS
$0.62
Previous year: $1.26
-50.8%
Gross Profit
$4B
Previous year: $5.13B
-21.9%
Cash and Equivalents
$6.5B
Previous year: $5.08B
+27.9%
Free Cash Flow
-$56M
Previous year: $1.21B
-104.6%
Total Assets
$93.9B
Previous year: $91.3B
+2.9%

Medtronic

Medtronic

Medtronic Revenue by Segment

Medtronic Revenue by Geographic Location

Forward Guidance

Given the uncertainty on near-term financial results caused by the COVID-19 pandemic, the company is not providing formal annual or quarterly financial guidance at this time.

Revenue & Expenses

Visualization of income flow from segment revenue to net income